Biotech News

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma (ATYR)aTyr Pharma2026-09-24 10:00 ESTFDA / regulatory

Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activities in the fourth quarter of 2026. SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

Related news

ATYRaTyr Pharma2026-09-01 20:36 EST

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

ATYRaTyr Pharma2026-08-07 20:01 EST

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

BMYBMYBristol-Myers Squibb Company2026-08-13 21:12 EST

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

XFORX4 Pharmaceuticals2026-09-08 11:00 EST

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

BNTXBioNTech2026-08-27 20:30 EST

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

TLSATiziana Life Sciences2026-09-30 11:00 EST

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

HCMHUTCHMED2026-09-29 00:00 EST

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

HCMHUTCHMED2026-08-28 00:00 EST

HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

REGNRegeneron Pharmaceuticals2026-08-19 17:58 EST

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

HCWBHCW Biologics2026-07-23 12:00 EST

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

View all latest news

aTyr Pharma

tRNA Synthetase Biology aTyr Pharma is a clinical-stage biotechnology company translating extracellular signaling functions of tRNA synthetases into therapies for fibrosis and inflammation. Its discovery platform searches domains derived from the 20 human tRNA synthetases for new therapeutic intervention points. Efzofitimod Efzofitimod...

Recent company news

ATYRaTyr Pharma2026-09-24 10:00 EST

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

ATYRaTyr Pharma2026-09-01 20:36 EST

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

ATYRaTyr Pharma2026-08-07 20:01 EST

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

ATYRaTyr Pharma2026-07-15 12:00 EST

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

ATYRaTyr Pharma2026-05-15 12:00 EST

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

Stock data

Close: 0.28 USD
Market cap: 50.99M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States